---
layout: default
title: Ribavirin
description: "Ribavirin çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚ä¸­ç­‰è­‰æ“šç­‰ç´š L3ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: ä¸­è­‰æ“šç­‰ç´š (L3-L4)
nav_order: 147
evidence_level: L3
indication_count: 10
---

# Ribavirin

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L3</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Ribavirinï¼šå¾ C å‹è‚ç‚åˆ°æ…¢æ€§ B å‹è‚ç‚ç—…æ¯’æ„ŸæŸ“

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Ribavirin å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Ribavirin æ˜¯ä¸€ç¨®æŠ—ç—…æ¯’è—¥ç‰©ï¼ŒåŸæœ¬èˆ‡å¹²æ“¾ç´ æˆ–å…¶ä»–æŠ—ç—…æ¯’è—¥ç‰©ä½µç”¨æ²»ç™‚æ…¢æ€§ C å‹è‚ç‚ã€‚TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**æ…¢æ€§ B å‹è‚ç‚ç—…æ¯’æ„ŸæŸ“ (Chronic Hepatitis B Virus Infection)** æœ‰æ•ˆï¼Œç›®å‰æœ‰ **30+ å€‹è‡¨åºŠè©¦é©—**æ”¯æŒé€™å€‹ç ”ç©¶æ–¹å‘ã€‚
</p>


## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | æ…¢æ€§ C å‹è‚ç‚ï¼ˆèˆ‡ peginterferon æˆ– DAA ä½µç”¨ï¼‰ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | chronic hepatitis B virus infectionã€hepatopulmonary syndromeã€early-onset familial noncirrhotic portal hypertensionã€idiopathic copper-associated cirrhosisã€hepatoportal sclerosisã€primitive portal vein thrombosisã€chronic hepatitis C virus infectionã€hepatic porphyriaã€IgG4-related pachymeningitisã€IgG4-related mesenteritis |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.86% |
| è­‰æ“šç­‰ç´š | L3 |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | å¤šå¼µ |
| å»ºè­°æ±ºç­– | Proceed with Guardrails |


## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. chronic hepatitis B virus infection</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">99.86%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content" markdown="1">

### ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

Ribavirin æ˜¯ä¸€ç¨®æ ¸è‹·é¡ä¼¼ç‰©ï¼Œå…·æœ‰å»£è­œæŠ—ç—…æ¯’æ´»æ€§ã€‚å®ƒçš„ä½œç”¨æ©Ÿè½‰åŒ…æ‹¬ï¼š
- æŠ‘åˆ¶ç—…æ¯’ RNA èšåˆé…¶
- èª˜å°ç—…æ¯’åŸºå› çµ„çªè®Š
- èª¿ç¯€å®¿ä¸»å…ç–«åæ‡‰

é›–ç„¶ ribavirin ä¸»è¦è¢«æ‰¹å‡†ç”¨æ–¼ C å‹è‚ç‚çš„æ²»ç™‚ï¼Œä½†å…¶å»£è­œæŠ—ç—…æ¯’æ´»æ€§ä½¿å…¶å°å…¶ä»–ç—…æ¯’ï¼ˆåŒ…æ‹¬ B å‹è‚ç‚ç—…æ¯’ï¼‰å¯èƒ½å…·æœ‰æ½›åœ¨ç™‚æ•ˆã€‚åœ¨æŸäº›æƒ…æ³ä¸‹ï¼Œç‰¹åˆ¥æ˜¯ B/C å‹è‚ç‚åˆä½µæ„ŸæŸ“æˆ– D å‹è‚ç‚ï¼ˆéœ€è¦ B å‹è‚ç‚ç—…æ¯’ä½œç‚ºè¼”åŠ©ç—…æ¯’ï¼‰çš„æ‚£è€…ä¸­ï¼Œribavirin èˆ‡å¹²æ“¾ç´ çš„çµ„åˆå·²è¢«ç ”ç©¶ã€‚

ç„¶è€Œï¼Œéœ€è¦æ³¨æ„çš„æ˜¯ï¼Œç›®å‰ B å‹è‚ç‚çš„æ¨™æº–æ²»ç™‚æ˜¯æ ¸è‹·é¡ä¼¼ç‰©ï¼ˆå¦‚ entecavirã€tenofovirï¼‰æˆ–å¹²æ“¾ç´ ï¼Œribavirin ä¸¦ä¸æ˜¯æ¨™æº–æ–¹æ¡ˆçš„ä¸€éƒ¨åˆ†ã€‚

### è‡¨åºŠè©¦é©—

| è©¦é©—ç·¨è™Ÿ | éšæ®µ | ç‹€æ…‹ | äººæ•¸ | ä¸»è¦ç™¼ç¾ |
|---------|------|------|------|---------|
| [NCT00117533](https://clinicaltrials.gov/study/NCT00117533) | Phase 4 | æœªçŸ¥ | 20 | Peginterferon alfa-2b + ribavirin æ²»ç™‚ B/D å‹è‚ç‚åˆä½µæ„ŸæŸ“ |
| [NCT01318694](https://clinicaltrials.gov/study/NCT01318694) | Phase 3 | å·²å®Œæˆ | 1081 | Alisporivir + peginterferon + ribavirin æ²»ç™‚ C å‹è‚ç‚ |

ï¼ˆæ³¨ï¼šå¤§å¤šæ•¸è‡¨åºŠè©¦é©—é‡å° C å‹è‚ç‚ï¼Œéƒ¨åˆ†æ¶‰åŠ B/C å‹åˆä½µæ„ŸæŸ“ï¼‰

### ç›¸é—œæ–‡ç»

ç›®å‰ä¸»è¦æ–‡ç»é›†ä¸­åœ¨ C å‹è‚ç‚æ²»ç™‚ï¼Œé‡å°å–®ç´” B å‹è‚ç‚ç—…æ¯’æ„ŸæŸ“çš„ç ”ç©¶æœ‰é™ã€‚

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. hepatopulmonary syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.57%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.57%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. early-onset familial noncirrhotic portal hypertension</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.57%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.57%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. idiopathic copper-associated cirrhosis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.57%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.57%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. hepatoportal sclerosis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.57%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.57%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. primitive portal vein thrombosis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.57%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.57%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. hepatic porphyria</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.50%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.50%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. IgG4-related pachymeningitis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.44%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.44%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. IgG4-related mesenteritis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.31%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.31%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. IgG4-related aortitis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.31%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.31%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| å¤šå¼µè¨±å¯è­‰ | é€Ÿå¨å¹²è»Ÿè† å›Š100æ¯«å…‹ç­‰ | è† å›Š/éŒ åŠ‘ | èˆ‡å¹²æ“¾ç´ æˆ– DAA ä½µç”¨æ²»ç™‚æ…¢æ€§ C å‹è‚ç‚ |

## å®‰å…¨æ€§è€ƒé‡

**ä¸»è¦è­¦èªï¼š**
- æº¶è¡€æ€§è²§è¡€ï¼šæœ€å¸¸è¦‹çš„åš´é‡ä¸è‰¯åæ‡‰
- è‡´ç•¸æ€§ï¼šå­•å©¦ç¦ç”¨ï¼Œæ²»ç™‚æœŸé–“åŠæ²»ç™‚å¾Œ 6 å€‹æœˆéœ€é¿å­•
- å¿ƒè‡Ÿæ¯’æ€§ï¼šå¯èƒ½åŠ é‡å¿ƒè‡Ÿç–¾ç—…

**ç¦å¿Œç—‡ï¼š**
- å¦Šå¨ æˆ–å¯èƒ½æ‡·å­•çš„å©¦å¥³
- åš´é‡å¿ƒè‡Ÿç–¾ç—…
- è¡€ç´…ç´ ç•°å¸¸
- è‡ªé«”å…ç–«æ€§è‚ç‚

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**high-fat foods** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šFood enhances the oral absorption and bioavailability of ribavirin.  Administration of a single oral dose of ribavirin following a high-fat meal delayed absorption (Tmax was doubled) but increased the...
- å»ºè­°ï¼šTo ensure maximal oral absorption, ribavirin should be administered with or immediately after a meal.

### è—¥ç‰©-è‰è—¥äº¤äº’ä½œç”¨ (DHI)

**è–ç´„ç¿°è‰ï¼ˆè²«è‘‰é€£ç¿¹ï¼‰** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šè–ç´„ç¿°è‰å¯èƒ½å½±éŸ¿æŠ—ç—…æ¯’è—¥ç‰©ä»£è¬
- å»ºè­°ï¼šé¿å…ä½µç”¨



### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**Anemia** ğŸŸ¢ Minor
- Oral ribavirin may cause anemia.  The decrease in hemoglobin generally occurs within 1 to 2 weeks after initiation of therapy and stabilizes by week 4.  Because significant anemia may adversely affect cardiac function, oral ribavirin should not be us...

**Lung Diseases** ğŸŸ¢ Minor
- The use of aerosolized ribavirin has been associated with deterioration in pulmonary function, most significantly in patients with chronic obstructive pulmonary disease or asthma.  Respiratory status should be monitored in all patients receiving aero...

**è…è‡Ÿç–¾ç—… (Kidney Diseases)** ğŸŸ¢ Minor
- Orally administered ribavirin is metabolized by the liver, and both parent drug and metabolites are eliminated by the kidney.  In patients with creatinine clearance between 10 and 30 mL/min, the mean area under the concentration-time curve has been s...

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šProceed with Guardrails**

**ç†ç”±ï¼š**
é›–ç„¶ ribavirin å…·æœ‰å»£è­œæŠ—ç—…æ¯’æ´»æ€§ï¼Œä¸”æœ‰ä¸€äº›ç ”ç©¶æ¢è¨å…¶åœ¨ B/D å‹è‚ç‚åˆä½µæ„ŸæŸ“ä¸­çš„æ‡‰ç”¨ï¼Œä½†ç›®å‰ç¼ºä¹å……åˆ†è­‰æ“šæ”¯æŒå–®ç¨ç”¨æ–¼æ…¢æ€§ B å‹è‚ç‚çš„æ²»ç™‚ã€‚ç¾æœ‰çš„ B å‹è‚ç‚æ¨™æº–æ²»ç™‚ï¼ˆentecavirã€tenofovirï¼‰å·²è­‰æ˜æœ‰æ•ˆä¸”å®‰å…¨ã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- é€²è¡Œå°ç…§è©¦é©—æ¯”è¼ƒ ribavirin èˆ‡ç¾æœ‰ B å‹è‚ç‚æ²»ç™‚çš„ç™‚æ•ˆ
- æ˜ç¢º ribavirin åœ¨ B å‹è‚ç‚æ²»ç™‚ä¸­çš„å®šä½ï¼ˆè¼”åŠ©æ²»ç™‚ï¼Ÿç‰¹å®šäºç¾¤ï¼Ÿï¼‰
- è©•ä¼°èˆ‡ç¾æœ‰æ ¸è‹·é¡ä¼¼ç‰©ä½µç”¨çš„å®‰å…¨æ€§å’Œç™‚æ•ˆ
- ç‰¹åˆ¥æ³¨æ„æº¶è¡€æ€§è²§è¡€ç­‰åš´é‡ä¸è‰¯åæ‡‰çš„ç›£æ¸¬


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Interferon Beta-1B]({{ "/drugs/interferon_beta-1b/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Alfacalcidol]({{ "/drugs/alfacalcidol/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Dupilumab]({{ "/drugs/dupilumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Acitretin]({{ "/drugs/acitretin/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Inositol]({{ "/drugs/inositol/" | relative_url }}) - è­‰æ“šç­‰ç´š L3

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Ribavirinè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/ribavirin/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_ribavirin,
  title = {Ribavirinè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/ribavirin/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
